The Global Fragment Based Drug Discovery Market is experiencing significant growth owing to increasing adoption of fragment based screening techniques for lead identification and optimization in drug development process. Fragment based screening offers advantages such as identification of hits with novel chemical scaffolds, reduction in attrition rates in later stages and expansion of chemical space. The technology enables screening of fragments, which are small molecules that bind weakly and promiscuously to target proteins, and uses biophysical methods to detect interactions. Screening large fragment libraries helps identify starting points for growing molecules into high-affinity drug-like leads.
The Global Fragment Based Drug Discovery Market is estimated to be valued at US$ 0.795 Bn in 2024 and is expected to exhibit a CAGR of 15.% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the Global Fragment Based Drug Discovery Market are Astex Pharmaceuticals, Beactica AB, Charles River Laboratories International, Inc., Evotec AG, Alveus Pharmaceuticals Pvt. Ltd.
The market is expected to witness significant growth opportunities due to increasing R&D investments by pharmaceutical companies in modern drug discovery approaches. Furthermore, growing adoption of integrated platforms offering fragment screening, hit expansion and hit-to-lead development is surging the demand.
Technological advancements in the field of fragment based screening such as NMR spectroscopy, X-ray crystallography, SPR, DSF are further enhancing hit identification capabilities and fueling the market growth.
Market Drivers
The Global Fragment Based Drug Discovery Market is primarily driven by rising drug discovery and development costs coupled with low success rates of conventional high-throughput screening approaches. Fragment based screening offers enhanced hit rates, novel chemical starting points and low attrition during lead optimization. Furthermore, growing importance of structural biology data and biophysics methods in drug design is positively impacting the adoption. Initiatives towards open innovation and collaborations between pharma-biotech companies and academic research institutions are further propelling the market expansion.
Current Challenges In The Industry:
The Global Fragment Based Drug Discovery Market is facing various challenges currently. As this technique relies on identifying biologically active small molecule fragments that bind to the target protein of interest with low molecular weight and low binding affinity, it is challenging for researchers to convert these fragment hits into drug candidates with desirable pharmacological and pharmaceutical properties. Converting weak binding fragments into stronger lead compounds with optimal drug-like properties requires extensive medicinal chemistry efforts. Additionally, obtaining high resolution 3D structures of protein-fragment complexes is crucial for fragment based drug design programs but determining such structures experimentally through techniques like X-ray crystallography is difficult and time consuming.
Developing robust biomarkers for molecular properties critical for drug development using fragment screening data is another major challenge. It is also not easy to identify potential toxicity issues at an early stage for fragments or lead compounds evolved from fragments. Developing novel biophysical screening technologies capable of rapid screening of large chemical libraries against multiple protein targets is critical but an ongoing challenge. The complexity of target biology and disease etiology poses difficulties in selecting the most relevant protein targets for fragment screening campaigns. Selecting a target, developing and optimizing screening assays requires substantial investment of time and resources. Computational methods and artificial intelligence could help address some of these challenges but require further technological advances.
SWOT Analysis
Strength: Fragment based screening allows exploring wider chemical diversity and identifying weakly binding starting points. This technique is also advantageous as it requires smaller amounts of test compounds.
Weakness: Converting low affinity fragments into drug candidates remains a major challenge due to difficulties in medicinal chemistry optimizations. Determining high resolution protein-fragment complex structures experimentally is also time consuming.
Opportunity: Advances in biophysical screening methods, structural biology techniques and artificial intelligence/machine learning approaches can help overcome some key challenges and accelerate drug discovery using fragments. Collaborations between academic labs and pharmaceutical companies can help maximized opportunities.
Threats: High investment required for setting up cutting-edge fragment screening infrastructure and expertise. Inability to address target and disease complexities poses risks. Emergence of newer drug discovery technologies like in silico screening threatens fragment based approach.
In terms of value, the Global Fragment Based Drug Discovery Market is currently concentrated in North America, particularly the US due to presence of many global pharmaceutical companies and contract research organizations. Asia Pacific region, especially China and India, is anticipated to be the fastest growing market during forecast period owing to increasing allocation on drug discovery research, favorable government policies and lower operation costs. Various global pharmaceutical firms are also shifting resources to Asia to benefit from these advantages.
What Are The Key Data Covered In This Global Fragment Based Drug Discovery Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Global Fragment Based Drug Discovery Market’s growth between 2024 and 2031.
:- Accurate calculation of the size of the Global Fragment Based Drug Discovery Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Global Fragment Based Drug Discovery Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Global Fragment Based Drug Discovery Market vendors
FAQ’s
Q.1 What are the main factors influencing the Global Fragment Based Drug Discovery Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Global Fragment Based Drug Discovery Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Global Fragment Based Drug Discovery Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author – Priya Pandey
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor’s degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya’s meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. LinkedIn Profile